New hope for kids with tough cancers: immunotherapy drug tested
NCT ID NCT02332668
First seen Apr 04, 2026 · Last updated Jun 13, 2026 · Updated 13 times
Summary
This study tests pembrolizumab, a drug that helps the immune system fight cancer, in children aged 6 months to 18 years with advanced melanoma, solid tumors, or lymphoma that has spread, returned, or not responded to other treatments. The main goal is to see if the drug can shrink tumors. The study is currently recruiting participants.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Call for Information (Investigational Site 0019)
RECRUITINGAurora, Colorado, 80045, United States
-
Call for Information (Investigational Site 0024)
RECRUITINGChicago, Illinois, 60637, United States
-
Call for Information (Investigational Site 0026)
RECRUITINGBoston, Massachusetts, 02445, United States
-
Call for Information (Investigational Site 0031)
RECRUITINGNew York, New York, 10032, United States
-
Call for Information (Investigational Site 0054)
RECRUITINGDallas, Texas, 75235, United States
-
Call for Information (Investigational Site 0070)
RECRUITINGFargo, North Dakota, 58102, United States
-
Call for Information (Investigational Site 0071)
RECRUITINGSioux Falls, South Dakota, 57117, United States
-
MSD Brasil
RECRUITINGSão Paulo, Brazil
Contact Phone: •••-•••-••••
-
MSD France
RECRUITINGParis, France
Contact Phone: •••-•••-••••
-
MSD Italia S.r.l.
RECRUITINGRome, Italy
Contact Phone: •••-•••-••••
-
MSD Korea LTD
RECRUITINGSeoul, 4130, South Korea
Contact Phone: •••-•••-••••
-
MSD Sharp & Dohme GmbH
RECRUITINGMünchen, Germany
Contact Phone: •••-•••-••••
-
MSD Sweden
RECRUITINGStockholm, Sweden
Contact Phone: •••-•••-••••
-
Merck Sharp & Dohme BV
RECRUITINGHaarlem, Netherlands
Contact Phone: •••-•••-••••
-
Merck Sharp & Dohme Co. Ltd.
RECRUITINGHod HaSharon, Israel
Contact Phone: •••-•••-••••
-
Merck Sharp & Dohme Lda.
RECRUITINGPaço de Arcos, Portugal
Contact Phone: •••-•••-••••
-
Merck Sharp & Dohme Ltd.
RECRUITINGLondon, United Kingdom
Contact Phone: •••-•••-••••
Conditions
Explore the condition pages connected to this study.